Sunshine Biopharma enters new employment agreements with CEO, CFO, COO; CEO severance of $14M USD

Sunshine Biopharma Inc.

CEO Dr. Slilaty: $543,753 CAD base salary, 5% or CPI annual increase, $14M USD severance for termination without cause or for good reason.
CFO Camille Sebaaly: $411,000 CAD base salary, 5% or CPI annual increase, $2M CAD severance for termination without cause.
COO Dr. Merzouki: $328,800 CAD base salary, 5% or CPI annual increase, $2M CAD severance for termination without cause.
All three executives to devote 90% of time to subsidiary Nora Pharma Inc.; agreements effective retroactive to January 1, 2024.
CEO's $14M USD severance is substantially larger relative to base salary than CFO and COO severance of $2M CAD each.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.